Barclays’s Aligos Therapeutics ALGS Stock Holding History

Barclays’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$6	Buy	+1	New	+$6	﹤0.01%	5220
2025 Q4	–	Sell	-15	Closed	-$147	–	5213
2025 Q3	$147	Buy	+15	New	+$137	﹤0.01%	5257
2022 Q3	–	Sell	-117	Closed	-$4K	–	4757
2022 Q2	$4K	Sell	117 -201	-63%	-$6.83K	﹤0.01%	4808
2022 Q1	$16K	Buy	+318	New	+$25.5K	﹤0.01%	4496

Other funds holding ALGS

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Golden State Wealth Management Santa Ana, California $1.1B AUM 19.2% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return

Barclays's ALGS Position: Q3 2026 in Review

Barclays opened a new position in Aligos Therapeutics (ALGS) in Q3 2026: 1 share worth $6. The stake represents ﹤0.01% of the portfolio and ranks #5220 among its holdings. This is a return to the name: Barclays previously reported a position in ALGS as recently as Q3 2025.

Barclays first reported a position in ALGS in Q1 2022 and has held it in 4 quarters since. The position peaked at $16K in Q1 2022. 7 funds tracked by Wall St. Rank hold ALGS as of Q3 2026.

Barclays held 1 share of Aligos Therapeutics worth $6 as of Q3 2026.
Aligos Therapeutics was a new Barclays position in Q3 2026.
Aligos Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #5220 holding.
Barclays first reported a position in Aligos Therapeutics in Q1 2022 and has held it in 4 quarters since.
Barclays's Aligos Therapeutics position peaked at $16K in Q1 2022.
7 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.